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OBJECTIVES
The aim of this study was to summarize shortly canine leishmaniasis, its ethiology, epidemiology and immunology,
clinical manifestation, diagnostic procedure, and finally, its treatment. Moreover, a very important point was to do an
update on the risks associated to allopurinol therapy in dogs with canine leishmaniasis, exemplifying them with four
retrospective clinical cases.
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WHAT IS LEISHMANIASIS?
Canine leishmaniasis (CanL) is an invasive disease
on dogs, caused by Leishmania spp. and transmitted
by the bite of an infected phlebotomine sand fly. It is
endemic in many countries and very common in
Mediterranean regions1.
CLINICAL SIGNS
Main clinical manifestations of CanL are non-
specific, such as limphadenomegaly, skin disorders
(A, D, E), progressive loss of weight and muscular
atrophy (B), apathy, onycogriphosis (C), vomiting,
diarrhea, polyuria and polydipsia, ocular (D), renal
and articular lesions 2.
XANTHINURIA
XANTHINE OXIDASE (XO) 
Hypoxanthine + Xanthine Uric acid
Congenit: xanthine oxidase deficiency
Allopurinol potentially increases
the risk of xanthine uroliths by
inhibiting xanthine oxidase enzyme.
This can result in many different manifestations, like
urinary sediment and uroliths without giving urinary
alterations, or dysuria and severe urinary tract
obstructions. Moreover, its consequences are much
variable too, such as renal failure or detrusor muscle
incompetence.
TREATMENT
There are many protocols of treatment for CanL, but
combination of antileishmanial drugs like meglumine
antimoniate, administered subcutaneous during 30
days (100mg/kg/24h), together with allopurinol
(10mg/kg/12h) administered orally, which is a
specifical leishmaniostatic drug, is the most
frequently chosen protocol1.
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A: xanthine urocystoliths.
B: renal  pelvic mineralization.
C: xanthine urolithiasis causing
uretral obstruction.
Images provided by Hospital 
Clínic Veterinari UAB.
CONCLUSIONS
1. Allopurinol therapy should be correctly monitored 
periodically through a complete urinalysis, (including 
sediment) and an abdominal echography, all along the 
treatment.
2. It is recommended to do a preventive treatment of  
xanthinuria with a low purine diet, specially in 
predisposed breeds.
3. Prospective studies and follow-up are necessary to
achieve the best outcome we can expect on treatment.
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